pocketful logo light
pocketful logo light
Biocon Ltd logo

Biocon Ltd

NSE: BIOCON BSE: 532523

₹415.50

(0.40%)

Tue, 23 Jun 2026, 04:43 am

mtf coin illustrationMTF 5x

Biocon Share Price Live Chart

1 Day

(0.40%)

No Result Found

Summary

  • Market Cap (in Cr)

    69415.38

  • Net Profit (in Cr)

    1429.4

  • P/B

    1.89

  • Sector P/E

    33.76

  • P/E

    40.43

  • EV/EBITDA

    12.35

  • Debt/Equity (Industry)

    0.29

  • Interest Cover (Industry)

    4.50

  • ROCE (Industry)

    9.39

  • RONW (Industry)

    7.26

  • ROE

    6.90

  • ROCE

    6.86

  • Debt/Equity

    0.84

  • EPS (TTM)

    2.40

  • Dividend Yield

    0.12

  • Book Value

    209.95

  • Interest Cover

    3.10

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters44.9154.4554.4554.4560.64
FII7.527.396.616.045.66
DII24.0721.7122.1022.8215.72
Public23.4916.4516.8316.6817.97
Government00000

Read More

Technical Analysis

RSI

65.80

MACD

4.52

50 DMA

397.54

200 DMA

381.34

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic571.82490.62459.63409.42378.43328.22247.02
Fibonacci490.62459.60440.44409.42378.40359.24328.22
Camarilla450.98443.54436.09409.42421.21413.76406.32

Pivots Level: Classic

R3

+162.40

571.82

R2

+81.20

490.62

R1

+50.22

459.63

409.42
409.42
Pivot Point
LTP: 431.20

S1

-30.98

378.43

S2

-81.20

328.22

S3

-162.40

247.02

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    419.21

  • 20-EMA

    416.65

  • 30-EMA

    412.52

  • 50-EMA

    404.63

  • 100-EMA

    393.70

  • 200-EMA

    382.91

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
07 May 2026board-meetingsAccounts, Final Dividend
07 May 2026dividend₹0.50 Dividend /Share03 Jul 2026
12 Feb 2026board-meetingsQuarterly Results
06 Dec 2025egm
11 Nov 2025board-meetingsQuarterly Results
04 Jun 2025dividendFinal Dividend - Rs. - 0.504 Jul 2025
08 May 2025agm
08 May 2025dividend₹0.50 Dividend /Share04 Jul 2025
05 Jun 2024dividendFinal Dividend - Rs. - 0.505 Jul 2024
16 May 2024dividend₹0.50 Dividend /Share05 Jul 2024

Read More

Peer Comparison

Biocon Ltd logo

Biocon Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Biocon Ltd About

Biocon is engaged in the manufacture of biotechnology products and research services.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1978

Headquarters

CEO

Kiran Mazumdar Shaw

Employees

Contact

Website icon

Website

http://www.biocon.com

Email icon

Email

co.secretary@biocon.com

Phone icon

Phone

91-80-28082808

Location icon

Location

20th KM Hosur Road Hebbagodi, Electronic City P O, Bangalore, Karnataka, 560100

Read More

Biocon Ltd Company History

YearHistory
2021
  • Biocon launches Everolimus tablets in US.
  • Biocon enters out-licensing deal with Tabuk Pharmaceuticals.
  • Biocon Biologics’ interchangeable biosimilar Insulin Glargine preferred on Express Scripts’ US formulary.
  • Biocon enters Dow Jones Sustainability Emerging Markets Index.
  • Biocon partners with Tabuk Pharmaceuticals for speciality generics in Middle East.
2022
  • Biocon initiates clinical study of Itolizumab for Ulcerative Colitis in India.
  • Biocon Biologics completes acquisition of Viatris’ Global Biosimilars Business.
  • Biocon enters commercialization agreement with Zentiva in Europe.
  • Biocon ranks No. 8 in ‘Global Top Employers’ List by Science Magazine.
  • Biocon Foundation receives ‘Mahatma Award 2022 for Excellence in Social Good.
  • Biocon Sdn. Bhd. enters Malaysia Book of Records as largest integrated insulin facility.
2023
  • Biocon partners with Sandoz for Adalimumab BS distribution in Japan.
  • Biocon recognized as Asia IP Elite 2023; IPR Team named Team of the Year.
  • Biocon completes integration of Viatris’ Biosimilar Business in 31 European countries.
  • Biocon signs commercialization agreement with Juno Pharmaceuticals in Canada.
  • Biocon acquires manufacturing facility of Eywa Pharma Inc.
  • Biocon Biologics takes over commercialization of biosimilars from Viatris in 70+ emerging markets.
2024
  • Biocon ranked among Science Magazine’s Top 10 Global Employers.
  • Biocon Foundation honored with ‘Doing Good for Bharat Awards 2024’ in Healthcare Category for ‘eLAJ Smart Clinics’.
  • Biocon partners with Tabuk Pharmaceuticals to commercialize GLP-1 products in Middle East.
  • Biocon Foundation and IISc organize OCTF Conference on AI in Oral Cancer.
  • Biocon signs semi-exclusive distribution deal for generic Saxenda (Liraglutide) in Mexico.
2025
  • Biocon Biologics wins 'Data Privacy Program of the Year' at BW Tech World’s Tech Excellence Awards.
  • Biocon Biologics wins two awards at Asia Pacific Biopharma Excellence Awards (ABEA).
  • Biocon honored with Champion of CSR Award at ESG Impact Summit 2024.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
THE JUPITER GLOBAL FUND-JUPITER INDIA SELECTblockBuy469049279.818 Jan 2024
JUPITER SOUTH ASIA INVESTMENT COMPANY LIMITEDblockSell469049279.818 Jan 2024
AHAN - I LTDbulkSell18928363200.7417 Mar 2023
INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.bulkBuy8061599229.2628 Feb 2023
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell500049281.0514 Nov 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy500049281.0514 Nov 2022
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell500049268.4503 Nov 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy500049268.4503 Nov 2022
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell466252270.125 Oct 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy466252270.125 Oct 2022

Read More

Biocon Ltd News

Biocon details TDS on FY26 dividend

Biocon outlines TDS rates for the ₹0.50 final dividend for FY26, with a record date of July 3, 2026.

22 Jun 2026

companies

Biocon declares no encumbrance on promoter shares

Biocon promoter group confirms no shares were encumbered in FY26. Declaration filed under SEBI SAST Regulations.

15 Jun 2026

companies

Biocon acquires stake in Ampin C&I Power Twelve

Biocon invested ₹5.48 crore for a 37.77% stake in Ampin C&I Power Twelve to support renewable energy goals and reduce costs.

10 Jun 2026

companies

Biocon to host Macquarie plant visit on June 11

Biocon Limited will host a plant visit for Macquarie's Healthcare Tour in Bangalore on June 11, 2026. The company confirmed no unpublished price sensitive information will be disclosed.

08 Jun 2026

companies

Biocon shareholders approve key resolutions

Biocon Limited shareholders approved resolutions regarding director appointments and remuneration revisions via postal ballot. The voting concluded on June 07, 2026.

08 Jun 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number